2018-04-07 09:36:00 Sat ET
technology antitrust competition bilateral trade free trade fair trade trade agreement trade surplus trade deficit multilateralism neoliberalism world trade organization regulation public utility current account compliance
Facebook CEO Mark Zuckerberg testifies in Congress to rise up to the challenge of public outrage in response to the Cambridge Analytica data debacle and user privacy breach of trust. His long congressional delivery before U.S. Senate seems wooden and stiff and sticks closely to his talking points without any major mistakes. It is clear from the outset that many of the senators are quite tech-illiterate, and the 33-year-old CEO has to explain some basic features of his social network platform. These basic features include Facebook advertisements, business fanpages, target audience segments, active user data distributions, privacy rules, and service terms and conditions etc. Zuckerberg reiterates his apologies for Russian interference in the November 2016 U.S. presidential election, Cambridge Analytica data debacle, and government regulation of social media firms such as Facebook and Twitter.
His answers to some of the tougher questions are less satisfactory, but Zuck never attempts to push back to fill the silence. For instance, a senator asks Zuck whether he would identify Twitter as its primary competitor. Zuck deflects the question to focus on the current size of Facebook as an online social community in comparison to a few platform orchestrators such as Apple, Amazon, Google, and Microsoft etc. The Cambridge Analytica data debacle affects 85+ million Facebook users, and many stock analysts and market commentators discuss the post-Cambridge crisis for Facebook.
Facebook faces fewer active users per month, and the average costs of Facebook ads inevitably surge as the target audience segments become less accurate. As active usage and social engagement both decline over time, Facebook has to deal with low sales revenue and bottomline because some business pages may further constrain their ad budgets on Facebook. The probable increase in Facebook ad expenses can be detrimental to business and non-commercial organizations that continue to maintain their online presence.
New government rules and regulations may entail subjecting Facebook and Twitter to the same media standards for publishers. Alternatively, new government rules and regulations may stipulate that Facebook has to break into smaller subsidiaries in comparison to the antitrust treatment of Microsoft and Google. The current crisis can deter Facebook from tapping into the uncharted territory of both e-commerce and entertainment industries.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2019-08-12 07:30:00 Monday ET
Facebook reaches a $5 billion settlement with the Federal Trade Commission over Cambridge Analytica user privacy violations. The Federal Trade Commission (F
2018-07-15 11:35:00 Sunday ET
Facebook, Google, and Twitter attend a U.S. House testimony on whether these social media titans filter web content for political reasons. These network pla
2026-01-19 10:30:00 Monday ET
Andy Yeh Alpha (AYA) fintech network platform: major milestones, key product features, and online social media services Introduction
2018-04-26 07:37:00 Thursday ET
Credit supply growth drives business cycle fluctuations and often sows the seeds of their own subsequent destruction. The global financial crisis from 2008
2018-08-21 11:40:00 Tuesday ET
President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike with greenback strength. This criticism overshado
2019-06-07 04:02:05 Friday ET
The world seeks to reduce medicine prices and other health care costs to better regulate big pharma. Nowadays the Trump administration requires pharmaceutic